Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study on patient outcomes after metal-on-metal hip replacement revision surgery has been selected as part of a prestigious 'Game Changers' session at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting.

The biggest study in the world of its kind, researchers specifically investigated outcomes after revision surgery performed for abnormal reactions to metal. The Program Committee for the conference, this year taking place in San Diego, selects work which they feel will change clinical practice within the next two to three years.

Approximately 1.5 million patients worldwide have metal-on-metal hip replacements for painful arthritis. Abnormal reactions to metal can develop which may cause surrounding tissue damage. Many patients with these reactions require further operations, known as revision surgery. Little is currently known about outcomes for patients following these further operations, though initial observations showed patients experienced poor results. This is concerning as most patients who received this type of hip replacement are young and active. Therefore poor results would have a significant impact on a patient's quality of life.

Read more (NDORMS website)

Similar stories

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.

Three NHSBT research units launch at University of Oxford

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.

COVID-19’s high blood clot risk

A recent study of patient health records found that around 1 in 100 people with COVID-19 had a venal or arterial thrombosis, with rates higher still among males, and particularly for those hospitalised.

Medical Sciences Division receives REF 2021 results

Today the UK Funding Bodies have published the outcomes of the recent national research assessment exercise, the Research Excellence Framework (REF) 2021. REF is the UK-wide assessment of research in universities, and provides an expert evaluation of the quality of the research outputs, impact and environment at subject level in each university.